No

Alpha/Beta Agonist; Ophthalmic Agent, Antiglaucoma; Ophthalmic Agent, Vasoconstrictor

Reduces elevated intraocular pressure in chronic open-angle glaucoma; also used to treat ocular hypertension, low tension, and secondary glaucomas

B

Hypersensitivity to dipivefrin, ingredients in the formulation, or epinephrine; contraindicated in patients with angle-closure glaucoma

Use with caution in patients with vascular hypertension or cardiac disorders and in aphakic patients; contains sodium metabisulfite

1% to 10%:

Central nervous system: Headache

Local: Burning, stinging

Ocular: Ocular congestion, photophobia, mydriasis, blurred vision, ocular pain, bulbar conjunctival follicles, blepharoconjunctivitis, cystoid macular edema

<1%: Arrhythmias, hypertension

Increased or synergistic effect when used with other agents to lower intraocular pressure

Avoid exposure to light and air; discolored or darkened solutions indicate loss of potency

Dipivefrin is a prodrug of epinephrine which is the active agent that stimulates alpha- and/or beta-adrenergic receptors increasing aqueous humor outflow

Ocular pressure effect:

Onset of action: Within 30 minutes

Duration: greater than or equal to 12 hours

Mydriasis:

Onset of action: May occur within 30 minutes

Duration: Several hours

Absorption: Rapid into the aqueous humor

Metabolism: Converted to epinephrine

Adults: Ophthalmic: Instill 1 drop every 12 hours into the eyes

None reported

None reported

No information available to require special precautions

No effects or complications reported

Discolored solutions should be discarded; may cause transient burning or stinging

Finger pressure should be applied to lacrimal sac for 1-2 minutes after instillation to decrease risk of absorption and systemic reactions

Solution, ophthalmic, as hydrochloride: 0.1% (5 mL, 10 mL, 15 mL)